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1. INTRODUCTION {#cas14337-sec-0001}
===============

The reprogramming of energy metabolism represented by the Warburg effect is a hallmark of cancer.[1](#cas14337-bib-0001){ref-type="ref"} The common feature of such altered cellular metabolism is increased glucose consumption and a shift from oxidative phosphorylation to glycolysis.[2](#cas14337-bib-0002){ref-type="ref"} Increased rates of glycolysis provide cancer cells with growth and survival advantages and are associated with tumor aggressiveness and malignancy.[3](#cas14337-bib-0003){ref-type="ref"}, [4](#cas14337-bib-0004){ref-type="ref"} The GLUT (*SLC2A*) family of glucose transporter proteins is a key regulator of glucose uptake across cell membranes.[5](#cas14337-bib-0005){ref-type="ref"} Among its 14 members, GLUT1 is broadly expressed in various cancer cells and plays a pivotal role in glycolytic metabolism.[6](#cas14337-bib-0006){ref-type="ref"} Interestingly, a recent report indicates that GLUT3 is also expressed in glioblastoma,[7](#cas14337-bib-0007){ref-type="ref"} colon cancer,[8](#cas14337-bib-0008){ref-type="ref"} and lung cancer,[9](#cas14337-bib-0009){ref-type="ref"} suggesting that GLUT3 also functions in metabolic activity in cancer cells.

The epithelial‐mesenchymal transition (EMT) plays essential roles in development, tissue regeneration, wound healing, and organ fibrosis.[10](#cas14337-bib-0010){ref-type="ref"} Transforming growth factor‐β (TGF‐β) functions to induce EMT[11](#cas14337-bib-0011){ref-type="ref"}, [12](#cas14337-bib-0012){ref-type="ref"} by increasing expression of the transcription factors Snail and zinc finger E‐box binding homeobox 1 (ZEB1), which repress epithelial markers such as E‐cadherin, and by inducing mesenchymal markers, such as vimentin.[13](#cas14337-bib-0013){ref-type="ref"}, [14](#cas14337-bib-0014){ref-type="ref"} In tumor cells, the EMT is associated with increased tumor cell invasion and metastasis.[15](#cas14337-bib-0015){ref-type="ref"} Interestingly, recent studies indicate that the EMT promotes changes in cancer metabolism, antagonizes cancer cell apoptosis and senescence, and increases immunosuppression.[10](#cas14337-bib-0010){ref-type="ref"}, [16](#cas14337-bib-0016){ref-type="ref"}

We have reported that angiopoietin‐like protein 2 (ANGPTL2), which functions as a proinflammatory mediator in various diseases, including cancer,[17](#cas14337-bib-0017){ref-type="ref"} promotes the EMT by activating the TGF‐β pathway in a chemically induced skin squamous cell carcinoma mouse model.[18](#cas14337-bib-0018){ref-type="ref"} We also showed that, in an autocrine/paracrine manner, tumor cell‐derived ANGPTL2 accelerates aggressive metastatic phenotypes in tumor cells by activating cell motility, invasiveness, and the EMT in human lung and breast cancers and osteosarcoma.[19](#cas14337-bib-0019){ref-type="ref"}, [20](#cas14337-bib-0020){ref-type="ref"}, [21](#cas14337-bib-0021){ref-type="ref"} However, ANGPTL2 function has not been studied in the context of cancer cell metabolism.

Here, we report that, in primary tumor cells from patients with lung cancer, *ANGPTL2* expression levels positively correlate with those of *GLUT3*, but not *GLUT1*. Our in vitro analysis using lung cancer cell lines revealed that tumor cell‐derived ANGPTL2 signaling through integrin α5β1 increases *GLUT3* expression by activating the TGF‐β‐ZEB1 pathway, thereby activating glycolytic metabolism in lung cancer cells.

2. MATERIALS AND METHODS {#cas14337-sec-0002}
========================

2.1. Human studies {#cas14337-sec-0003}
------------------

Tissue samples were resected from 96 lung cancer patients at the Department of Thoracic Surgery of Kumamoto University Hospital. All specimens were diagnosed as lung cancer by a pathologist. All studies were approved by the Ethics Committee of Kumamoto University.

2.2. Immunohistological staining {#cas14337-sec-0004}
--------------------------------

Formalin‐fixed, paraffin‐embedded specimens were cut into 4‐μm sections and deparaffinized. Sections were autoclaved with citrate buffer (pH 6.0) for antigen retrieval. Sections were incubated with 3% H~2~O~2~ for 5 minutes to block endogenous peroxidase activity and then incubated with anti‐ANGPTL2 Ab and anti‐GLUT3 (1:100, HPA006539; Sigma‐Aldrich), diluted with Block Ace (KAC) at 4°C overnight. After washing with PBS, sections were incubated for 30 minutes with EnVision+ System‐HRP‐labeled Polymer Anti‐rabbit (Dako) for visualization with DAB (Dojindo). Slides were counterstained 20 seconds with hematoxylin.

2.3. Total RNA extraction and real‐time quantitative RT‐PCR {#cas14337-sec-0005}
-----------------------------------------------------------

Total RNA was isolated from cells using TRIzol reagent (Invitrogen) and from human tissue samples using the Total RNA Extraction Miniprep System (Viogene). DNase‐treated RNA was reversed‐transcribed using a PrimeScript RT reagent kit (Takara Bio). The PCR products were analyzed using a Thermal Cycler Dice Real Time System (Takara Bio). The PCR primer sequences are shown in Table [S1](#cas14337-sup-0001){ref-type="supplementary-material"}. Relative transcript abundance was normalized to that of *RPS18* mRNA.

2.4. Cell culture {#cas14337-sec-0006}
-----------------

The human lung cancer lines NCI‐H460 (H460) and NCI‐H460‐LNM35 (LNM35) were previously described[22](#cas14337-bib-0022){ref-type="ref"} and provided by Dr T. Takahashi (Aichi Cancer Center, Japan). NCI‐H1975 (H1975) was purchased from ATCC. HCC15 (H15) was established at the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center[23](#cas14337-bib-0023){ref-type="ref"} and generously donated by Dr Adi F. Gazdar (University of Texas Southwestern Medical Center). H460, LNM35, H1975, and H15 cells were cultured in RPMI‐1640 medium supplemented with 10% FCS at 37°C in a humidified 5% CO~2~ atmosphere. For some experiments, cells were treated with 10 μM MEK inhibitor U0126 (662005; Millipore) for 6 h in normal growth medium.

2.5. Plasmid transfection {#cas14337-sec-0007}
-------------------------

For stable transfection, H460, H1975, and H15 cells were transfected with ANGPTL2 or empty vectors[24](#cas14337-bib-0024){ref-type="ref"} using Lipofectamine 2000 (Invitrogen) according to the manufacturer\'s protocol and selected in 400‐800 μg/mL G418.

2.6. Immunoblot analysis {#cas14337-sec-0008}
------------------------

Solubilized proteins were subjected to SDS‐PAGE, and proteins were electrotransferred to PVDF membranes. Immunoblotting was carried out with Abs against ANGPTL2 (1:2000, BAF1444; R&D Systems) and Hsc70 (1:2000, \#sc7298; Santa Cruz Biotechnology). Immunodetection was carried out using an ECL kit (GE Healthcare) according to the manufacturer\'s protocol.

2.7. Flow cytometry {#cas14337-sec-0009}
-------------------

Cells were suspended in MACS buffer (Miltenyi Biotec) and stained with the following Abs: anti‐GLUT3 (ab15311; Abcam), anti‐integrin α5β1 (MAB1969; Millipore), anti‐integrin αvβ3 (MAB1976Z; Millipore), anti‐integrin αvβ5 (MAB1961; Millipore), and anti‐integrin α9β1 (Sc‐59969; Santa Cruz Biotechnology). Cells were incubated with appropriate secondary Abs. Viable cells were identified as unstained with 7‐AAD (Beckman Coulter). Stained cells were analyzed by BD FACSVerse (BD Biosciences). Data analysis was undertaken using FlowJo software (TreeStar).

2.8. Glucose uptake and lactate production assays {#cas14337-sec-0010}
-------------------------------------------------

Glucose uptake was determined using a Glucose Uptake‐Glo Assay (Promega) and lactate production by using a Lactate Assay Kit‐WST (Dojindo), according to each manufacturer\'s protocols.

2.9. Immunofluorescence {#cas14337-sec-0011}
-----------------------

For ZEB1 staining, cells were first fixed for 20 minutes in acetone and ethanol (1:1) and then blocked in 5% normal goat serum (Nichirei Biosciences). Cells were incubated with anti‐ZEB1 Abs (1:50, \#sc515797; Santa Cruz Biotechnology) and then with Alexa 488‐conjugated anti‐mouse Abs. Nuclei were counterstained with DAPI.

2.10. Knockdown of ZEB1 {#cas14337-sec-0012}
-----------------------

H460 cells were reseeded in 12‐well plates and transfected with *ZEB1* siRNA (SYK \[ID SR304746\] Trilencer‐27 human siRNA; OriGene). As a control, we used Trilencer‐27 Universal Scrambled Negative Control (OriGene). Total RNA was extracted for quantitative RT‐PCR (qRT‐PCR) analysis 24 hours later.

2.11. Knockdown of ANGPTL2 {#cas14337-sec-0013}
--------------------------

*ANGPTL2*‐specific knockdown LNM35 cells was described previously.[19](#cas14337-bib-0019){ref-type="ref"}

2.12. Statistical analyses {#cas14337-sec-0014}
--------------------------

Statistical analyses were undertaken using GraphPad Prism 8 software (GraphPad Software). Statistical parameters and methods are reported in figures and corresponding legends. Results with *P* values less than .05 were considered significant (\**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001). Comparisons between 2 groups were carried out using the unpaired 2‐tailed *t* test. Comparisons between 3 or more groups were undertaken using one‐way ANOVA with Tukey\'s multiple comparison test. Potential correlations of *ANGPTL2*, GLUT1 (*SLC2A1*), GLUT3 (*SLC2A3*), or *ZEB1* expression in lung cancer specimens were evaluated by calculating Spearman\'s correlation coefficient.

3. RESULTS {#cas14337-sec-0015}
==========

3.1. Glucose transport 3 abundantly expressed in aggressive lung cancer cells {#cas14337-sec-0016}
-----------------------------------------------------------------------------

The NCI‐H460‐LNM35 (LNM35) line is a highly metastatic subline of the human large‐cell lung carcinoma cell line NCI‐H460 (H460).[22](#cas14337-bib-0022){ref-type="ref"} Because enhanced glycolytic metabolism is reportedly associated with tumor aggressiveness,[4](#cas14337-bib-0004){ref-type="ref"}, [25](#cas14337-bib-0025){ref-type="ref"} we asked whether LNM35 and H460 cells differed in terms of glycolytic metabolism by comparing glucose uptake and lactate production in both lines. Both glucose uptake and lactate production were significantly increased in LNM35 relative to H460 cells (Figure [1](#cas14337-fig-0001){ref-type="fig"}A,B), suggesting activation of glycolytic metabolism in the highly metastatic line.

![Aggressive lung cancer cells show increased glycolytic metabolism and glucose transporter 3 (GLUT3) expression. A, Relative glucose uptake in H460 and LNM35 cells. Levels in H460 cells were set to 1. Data are means ± SD; n = 3 per group. \*\*\**P* \< .001, unpaired *t* test. B, Relative lactate production in H460 and LNM35 cells. Levels in H460 cells were set to 1. Data are means ± SD; n = 4 per group. \*\*\**P* \< .001, unpaired *t* test. C, Comparison of levels of GLUT1‐4 (*SLC2A1‐4*) transcripts in H460 and LNM35 cells. Levels in H460 cells were set to 1. Data are means ± SD; n = 3 per group. nd, not detected. \*\**P* \< .01, unpaired *t* test. D, Comparison of levels of indicated transcripts in H460 and LNM35 cells. Levels in H460 cells were set to 1. Data are means ± SD; n = 3 per group. \**P* \< .05, unpaired *t* test. ALDOA, aldolase fructose‐bisphosphate A; ENO, enolase; HK, hexokinase; LDHA, lactate dehydrogenase A;PFKM, phosphofructokinase muscle; PFKP, phosphofructokinase platelets; PGK1, phosphoglycerate kinase 1; PKM, pyruvate kinase M](CAS-111-1241-g001){#cas14337-fig-0001}

As GLUT family glucose transporters are critical for glucose transport and reportedly contribute to tumor progression in various cancers, including lung cancer,[6](#cas14337-bib-0006){ref-type="ref"}, [26](#cas14337-bib-0026){ref-type="ref"}, [27](#cas14337-bib-0027){ref-type="ref"} we compared expression levels of *GLUT1* (*SLC2A1*), *GLUT2* (*SLC2A2*), *GLUT3* (*SLC2A3*), and *GLUT4* (*SLC2A4*) in H460 and LNM35 cells. Interestingly, *GLUT1*, *GLUT2*, and *GLUT4* expression was comparable in both lines, whereas expression levels of *GLUT3* in LNM35 cells were significantly higher than in H460 cells (Figure [1](#cas14337-fig-0001){ref-type="fig"}C). To further investigate factors potentially accelerating glucose uptake and lactate production in LNM35 cells, we compared expression of transcripts encoding the glycolytic enzymes hexokinase 1 (*HK1*), hexokinase 2 (*HK2*), phosphofructokinase muscle (*PFKM*), phosphofructokinase platelets (*PFKP*), aldolase fructose‐bisphosphate a (*ALDOA*), phosphoglycerate kinase 1 (*PGK1*), enolase 1 (*ENO1*), enolase 2 (*ENO2*), pyruvate kinase M (*PKM*), and lactate dehydrogenase A (*LDHA*) in H460 and LNM35 cells (Figure [1](#cas14337-fig-0001){ref-type="fig"}D). Quantitative RT‐PCR analysis revealed that *PFKP*, *ALDOA*, *PGK1*, *PKM*, and *LDHA* mRNA levels were slightly higher in LNM35 cells than in H460 cells. These results suggest that enhanced glycolytic metabolism seen in LNM35 cells might be primarily attributable to increased GLUT3 expression in LNM35 relative to H460 cells.

3.2. Angiopoietin‐like protein 2 expression induces GLUT3 expression and enhances glycolytic metabolism in lung cancer cells {#cas14337-sec-0017}
----------------------------------------------------------------------------------------------------------------------------

We previously reported that increased metastatic ability of LNM35 relative to H460 cells is due to significant activation of ANGPTL2‐dependent tumor cell motility and invasiveness in LNM35 cells.[19](#cas14337-bib-0019){ref-type="ref"} Accordingly, *ANGPTL2* transcripts were more abundant in LNM35 than in H460 cells (Figure [2](#cas14337-fig-0002){ref-type="fig"}A). Here, we also found that LNM35 cells show increased *GLUT3* expression and enhanced glycolytic metabolism compared to H460 cells, as shown in Figure [1](#cas14337-fig-0001){ref-type="fig"}. These findings suggest that ANGPTL2 activity is linked to metabolic preference in tumor cells. To assess this possibility, we established 2 independent H460 cell lines, 1 overexpressing ANGPTL2 (H460/ANGPTL2) and the other a control H460 line overexpressing empty vector (H460/vector) (Figure [2](#cas14337-fig-0002){ref-type="fig"}B), and compared glucose uptake and lactate production in both (Figure [2](#cas14337-fig-0002){ref-type="fig"}C,D). Glucose uptake and lactate production in H460/ANGPTL2 lines were significantly increased relative to corresponding activities in control H460/vector cells. Moreover, expression levels of *GLUT3*, but not *GLUT1,* in the H460/ANGPTL2 line was markedly increased relative to expression in control H460/vector cells (Figure [2](#cas14337-fig-0002){ref-type="fig"}E). Consistently, FACS analysis with an anti‐GLUT3 Ab revealed an increase in GLUT3 protein levels on the surface of H460/ANGPTL2 relative to control H460/vector cells (Figure [2](#cas14337-fig-0002){ref-type="fig"}F).

![Angiopoietin‐like protein 2 (ANGPTL2) increases glucose transporter 3 (GLUT3) expression and glycolytic metabolism. A, Comparison of levels of *ANGPTL2* transcripts in H460 and LNM35 cells. Levels in H460 cells were set to 1. Data are means ± SD; n = 3 per group. \**P* \< .05, unpaired *t* test. B, Representative immunoblotting for ANGPTL2 in H460/ANGPTL2 and H460/vector cells. Heat shock cognate protein 70 (HSC70) served as a loading control. C, Relative glucose uptake in H460/ANGPTL2 and H460/vector cells. Levels in H460/vector cells were set to 1. Data are means ± SD; n = 6 per group. \**P* \< .05, \*\**P* \< .01, one‐way ANOVA test followed by Tukey\'s multiple comparison test. D, Relative lactate production in H460/ANGPTL2 and H460/vector cells. Levels in H460/vector cells were set to 1. Data are means ± SD; n = 3 per group. \*\*\**P* \< .001, one‐way ANOVA test followed by Tukey\'s multiple comparison test. E, Comparison of levels of GLUT1 (*SLC2A1*) and GLUT3 (*SLC2A3*) transcripts in H460/ANGPTL2 and H460/vector cells. Levels in H460/vector cells were set to 1. Data are means ± SD; n = 3 per group. \*\**P* \< .01, one‐way ANOVA test followed by Tukey\'s multiple comparison test. F, Representative profiles showing cell surface expression of GLUT3 (black line traces) or isotype‐matched control (gray filled traces) in H460/ANGPTL2 and H460/vector cells, as assessed by flow cytometry analysis. Gating of living cells was carried out after background assessment. MFI, median fluorescence intensity. G, Representative immunoblotting for ANGPTL2 in H1975/ANGPTL2 and H1975/vector cells, and in H15/ANGPTL2 and H15/vector cells. HSC70 served as a loading control. H, I, Relative glucose uptake and lactate production in H1975/ANGPTL2 and control cells, and H15/ANGPTL2 and control cells. Levels in respective vector control cells were set to 1. Data are means ± SD; n = 3 per group. \*\**P* \< .01, \*\*\**P* \< .001, one‐way ANOVA test followed by Tukey\'s multiple comparison test. J, K, Comparison of levels of GLUT1 (*SLC2A1*) and GLUT3 (*SLC2A3*) transcripts in H1975/ANGPTL2 and control cells, and H15/ANGPTL2 and control cells. Levels in respective vector control cells were set to 1. Data are means ± SD; n = 3 per group. \*\**P* \< .01, \*\*\**P* \< .001, one‐way ANOVA test followed by Tukey\'s multiple comparison test](CAS-111-1241-g002){#cas14337-fig-0002}

To assess whether ANGPTL2 activity alters *GLUT3* expression in other lung cancer lines, we established 2 additional ANGPTL2‐overexpressing lines plus corresponding controls: the human lung adenocarcinoma line H1975 (H1975/ANGPTL2 and H1975/vector) and the human lung squamous cell carcinoma line H15 (H15/ANGPTL2 and H15/vector) (Figure [2](#cas14337-fig-0002){ref-type="fig"}G). As in H460 cells, glucose uptake and lactate production in H1975/ANGPTL2 and H15/ANGPTL2 lines were significantly increased relative to corresponding controls (Figure [2](#cas14337-fig-0002){ref-type="fig"}H,I). Quantitative RT‐PCR revealed that expression levels of *GLUT3* in H1975/ANGPTL2 and H15/ANGPTL2 were higher than in control cells (Figure [2](#cas14337-fig-0002){ref-type="fig"}J,K). Taken together, these results suggest that ANGPTL2 enhances glycolytic metabolism in lung cancer cells by increasing GLUT3‐dependent glucose transport.

3.3. Angiopoietin‐like protein 2 induces GLUT3 expression through the TGF‐β--ZEB1 pathway {#cas14337-sec-0018}
-----------------------------------------------------------------------------------------

We next asked how ANGPTL2 increases *GLUT3* expression in lung cancer cells. Glucose transporter 3 transcription is reportedly regulated by the DNA binding protein ZEB1, which is upregulated by TGF‐β signaling during the EMT in nonsmall‐cell lung cancer cells.[26](#cas14337-bib-0026){ref-type="ref"} Furthermore, we previously reported that ANGPTL2 promotes the EMT by activating the TGF‐β pathway.[18](#cas14337-bib-0018){ref-type="ref"} Based on these findings, we hypothesized that ANGPTL2 induces *GLUT3* expression in lung cancer cells by activating TGF‐β‐induced ZEB1 expression. To assess this possibility, we first investigated the EMT status of H460/ANGPTL2 and H460/vector control cells (Figure [3](#cas14337-fig-0003){ref-type="fig"}A). Expression levels of *CDH1* (E‐cadherin), an epithelial marker, in H460/ANGPTL2 cells were markedly lower than those seen in control H460/vector cells. By contrast, expression levels of *VIM* (vimentin), a mesenchymal marker, in H460/ANGPTL2 cells were significantly higher than those seen in control H460/vector cells. Consistently, we found significantly increased expression of *TGFB1* (TGF‐β1) and the EMT‐associated transcription factors *ZEB1* and *SNAI1* in H460/ANGPTL2 relative to control H460/vector cells (Figure [3](#cas14337-fig-0003){ref-type="fig"}B). Furthermore, *TGFB1* and *ZEB1* transcript levels were higher in H1975/ANGPTL2 and H15/ANGPTL2 than in corresponding control cells (Figure [3](#cas14337-fig-0003){ref-type="fig"}C,D). We also observed increased nuclear accumulation of ZEB1 in H460/ANGPTL2 relative to control H460/vector cells (Figure [3](#cas14337-fig-0003){ref-type="fig"}E,F). These results suggest that tumor cell‐derived ANGPTL2 increases GLUT3 expression by activating both the TGF‐β1‐ZEB1 pathway and the EMT.

![Angiopoietin‐like protein 2 (ANGPTL2) induces glucose transporter 3 GLUT3 expression through zinc finger E‐box binding homeobox 1 (ZEB1). A, B, Comparison of levels of indicated transcripts in H460/ANGPTL2 and H460/vector cells. Levels seen in H460/vector cells were set to 1. Data are means ± SD; n = 3 per group. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001, one‐way ANOVA test followed by Tukey\'s multiple comparison test. C, D, Comparison of levels of indicated transcripts in H1975/ANGPTL2 and control cells, and in H15/ANGPTL2 and control cells. Levels in respective vector control cells were set to 1. Data are means ± SD; n = 3 per group. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001, one‐way ANOVA test followed by Tukey\'s multiple comparison test. E, Immunofluorescent staining for ZEB1 (green) in H460/ANGPTL2 and H460/vector cells. Nuclei are counterstained with DAPI (blue). Scale bar = 100 μm. Insets show magnified images. F, Quantification of ZEB1‐positive nuclei. Data are means ± SD; n = 8 per group. \**P* \< .05, unpaired *t* test. G, H, Comparison of levels of indicated transcripts in H460/ANGPTL2 and H460/vector cells transfected with ZEB1‐specific siRNAs (siZEB1\#1 or siZEB1\#2) or negative control siRNA (siControl). Levels in control siRNA H460/vector cells were set to 1. Data are means ± SD; n = 3 per group. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001, one‐way ANOVA followed by Tukey\'s multiple comparison test](CAS-111-1241-g003){#cas14337-fig-0003}

We then asked whether *GLUT3* expression in lung cancer cells changes after suppression of *ZEB1* expression in H460/ANGPTL2 and H460/vector cells. To do so, we transfected both lines with either *ZEB1*‐specific siRNAs (siZEB1\#1 and siZEB1\#2) or control scramble siRNA (siControl) (Figure [3](#cas14337-fig-0003){ref-type="fig"}G,H). *ZEB1* knockdown in H460/ANGPTL2 cells significantly decreased *GLUT3* expression, whereas we observed no change in *GLUT3* expression in siControl‐transfected H460/ANGPTL2 cells (Figure [3](#cas14337-fig-0003){ref-type="fig"}H). Interestingly, we observed no change in *GLUT3* expression in H460/vector cells, even in *ZEB1* knockdown cells (Figure [3](#cas14337-fig-0003){ref-type="fig"}G,H). Thus, we conclude that increased *GLUT3* expression due to ANGPTL2 expression is due to ZEB1 upregulation, suggesting that ANGPTL2 activates the TGF‐β‐ZEB1 pathway and increases GLUT3 expression.

3.4. Angiopoietin‐like protein 2 signaling through integrin α5β1 increases ZEB1‐mediated GLUT3 expression {#cas14337-sec-0019}
---------------------------------------------------------------------------------------------------------

We next assessed molecular mechanisms underlying ANGPTL2‐mediated activation of the TGF‐β‐ZEB1 pathway. As ANGPTL2 signaling through integrin α5β1 enhances cancer cell metastasis, including EMT activation,[20](#cas14337-bib-0020){ref-type="ref"}, [21](#cas14337-bib-0021){ref-type="ref"} we evaluated integrins expressed on the H460 cell surface by flow cytometry. As shown in Figure [4](#cas14337-fig-0004){ref-type="fig"}A, integrin α5β1 is expressed on H460 cells, suggesting that ANGPTL2 activates TGF‐β‐ZEB1 signaling through this receptor. Accordingly, *TGFB1* and *ZEB1* expression significantly decreased in H460/ANGPTL2 cells treated by an anti‐integrin α5β1 blocking Ab (α5β1 Ab) as compared to a control IgG‐treated (cIgG) group (Figure [4](#cas14337-fig-0004){ref-type="fig"}B). Signaling through the ANGPTL2‐integrin α5β1 axis reportedly activates ERK signaling and subsequent TGF‐β expression.[28](#cas14337-bib-0028){ref-type="ref"} Indeed, qRT‐PCR analysis revealed that *TGFB1* transcript levels were significantly decreased following treatment of H460/ANGPTL2 cells with the MEK inhibitor U0126 (Figure [4](#cas14337-fig-0004){ref-type="fig"}C), suggesting that ANGPTL2 could upregulate *TGFB1* through integrin α5β1‐ERK signaling. Furthermore, *GLUT3* induction in H460/ANGPTL2 cells was significantly suppressed after cells were treated with integrin α5β1 blocking Ab (Figure [4](#cas14337-fig-0004){ref-type="fig"}D). Collectively, these results suggest that tumor cell‐derived ANGPTL2 autocrine/paracrine signaling through integrin α5β1 increases GLUT3 expression by activating the TGF‐β‐ZEB1 pathway.

![Angiopoietin‐like protein 2 (ANGPTL2) induces zinc finger E‐box binding homeobox 1 (ZEB1)‐dependent glucose transporter 3 (GLUT3) expression through integrin α5β1. A, Typical profiles of cell surface expression of integrins in H460 cells, as assessed by flow cytometry. Gating of living cells was carried out after background assessment. B, Comparison of levels of indicated transcripts in H460/ANGPTL2 and H460/vector cells treated with integrin α5β1‐blocking Ab or control IgG (cIgG). Levels in H460/vector cells treated with control IgG were set to 1. Data are means ± SD; n = 3 per group. \*\**P* \< .01, \*\*\**P* \< .001, one‐way ANOVA followed by Tukey\'s multiple comparison test. C, Comparison of levels of *TGFB1* transcripts in H460/ANGPTL2 and H460/vector control cells, either nontreated or treated with the MEK inhibitor U0126. Levels in vector control cells were set to 1. Data are means ± SD; n = 3 per group. \*\*\**P* \< .001, one‐way ANOVA followed by Tukey\'s multiple comparison test. D, Comparison of levels of GLUT3 (*SLC2A3*) transcripts in H460/ANGPTL2 and H460/vector cells treated with integrin α5β1‐blocking Abs or cIgG. Levels in H460/vector cells treated with control IgG were set to 1. Data are means ± SD; n = 3 per group. \*\**P* \< .01, \*\*\**P* \< .001, one‐way ANOVA followed by Tukey\'s multiple comparison test](CAS-111-1241-g004){#cas14337-fig-0004}

3.5. Angiopoietin‐like protein 2 knockdown reduces glycolytic metabolism in aggressive lung cancer cells {#cas14337-sec-0020}
--------------------------------------------------------------------------------------------------------

To confirm ANGPTL2 function in metabolic reprogramming of lung cancer cells, we generated 3 independent LNM35 cell sublines expressing a microRNA‐mediated RNA interference expression vector designed to knockdown *ANGPTL2,* namely, miANGPTL2\#1, miANGPTL2\#2, and *LacZ* (miLacZ) (Figure [5](#cas14337-fig-0005){ref-type="fig"}A). Expression of *TGFB1*, *ZEB1*, and *GLUT3* in both LNM35/miANGPTL2\#1 and LNM35/miANGPTL2\#2 cells was significantly decreased relative to LNM35/miLacZ cells (Figure [5](#cas14337-fig-0005){ref-type="fig"}B,C). Moreover, glucose uptake and lactate production in both LNM35/miANGPTL2\#1 and LNM35/miANGPTL2\#2 cells were significantly reduced compared to levels seen in control LNM35/miLacZ cells (Figure [5](#cas14337-fig-0005){ref-type="fig"}D,E). We conclude that tumor cell‐derived ANGPTL2 autocrine/paracrine signaling drives glycolytic metabolism phenotypes in lung cancer cells.

![Angiopoietin‐like protein 2 (ANGPTL2) knockdown in lung cancer cells decreases glycolytic metabolism. A‐C, Comparison of levels of indicated transcripts in ANGPTL2 knockdown (miANGPTL2\#1 and miANGPTL2\#2) and control (miLacZ) LNM35 cells. Levels in control cells were set to 1. Data are means ± SD; n = 3 per group. \*\**P* \< .01, \*\*\**P* \< .001, one‐way ANOVA followed by Tukey\'s multiple comparison test. D, Relative glucose uptake in ANGPTL2 knockdown and control LNM35 lines. Levels in control cells were set to 1. Data are means ± SD; n = 3 per group. \**P* \< .05, \*\**P* \< .01, one‐way ANOVA followed by Tukey\'s multiple comparison test. E, Relative lactate production in ANGPTL2 knockdown and control LNM35 lines. Levels in control cells were set to 1. Data are means ± SD; n = 3 per group. \*\*\**P* \< .001, one‐way ANOVA followed by Tukey\'s multiple comparison test](CAS-111-1241-g005){#cas14337-fig-0005}

3.6. Angiopoietin‐like protein 2 expression in primary tumor tissues correlates with GLUT3 expression {#cas14337-sec-0021}
-----------------------------------------------------------------------------------------------------

Finally, we assessed a potential correlation in *ANGPTL2*, *GLUT3*, and *ZEB1* mRNA expression levels in primary tumor tissues from 96 lung cancer patients (Figure [6](#cas14337-fig-0006){ref-type="fig"}A). *ANGPTL2* expression was positively correlated with *GLUT3* and *ZEB1* expression in these specimens (*r* = .3536 and *r* = .5676), whereas we observed no correlation between *ANGPTL2* and *GLUT1* expression in these samples (*r* = .0716). Furthermore, we observed a positive correlation between *ZEB1* and *GLUT3* expression in these specimens (*r* = .6788). Immunohistochemical analysis of surgical specimens of primary tumors from patients with lung cancer using anti‐ANGPTL2 and anti‐GLUT3 Abs revealed relatively less GLUT3 expression in tumor tissues expressing low ANGPTL2 protein (Figure [6](#cas14337-fig-0006){ref-type="fig"}B, patients 1 and 2). By contrast, lung cancer cells expressing abundant ANGPTL2 protein showed high GLUT3 expression (Figure [6](#cas14337-fig-0006){ref-type="fig"}B, patients 3 and 4).

![Angiopoietin‐like protein 2 (ANGPTL2) expression correlates with glucose transporter 3 (GLUT3) expression in human lung cancer. A, Correlation between (upper) *ANGPTL2* and GLUT1 (*SLC2A1*) or *ANGPTL2* and GLUT3 (*SLC2A3*) or (lower) *ZEB1* and *ANGPTL2* or *ZEB1* and GLUT3 (*SLC2A3*) expression in primary tumor tissues from lung cancer patients (n = 96). Relative transcript abundance was normalized to that of *RPS18* mRNA. Spearman\'s correlation coefficient (*r*) was calculated as 0.0716 (upper left), 0.3536 (upper right), 0.5676 (lower left), and 0.6788 (lower right). B, Immunostaining for ANGPTL2 and GLUT3 in surgical specimens of primary tumors from 4 indicated patients with lung cancer. Scale bar = 100 μm](CAS-111-1241-g006){#cas14337-fig-0006}

4. DISCUSSION {#cas14337-sec-0022}
=============

Here, we provide evidence supporting a role for tumor cell‐derived ANGPTL2 in promoting glycolytic metabolism in lung cancer cells. We report that a highly metastatic subline of a human large‐cell lung carcinoma cell line showing high ANGPTL2 expression showed enhanced glycolytic metabolism and increased GLUT3 expression compared with the less metastatic parental line. Mechanistically, through autocrine/paracrine signaling, tumor cell‐derived ANGPTL2 signaling through integrin α5β1--ERK signaling increased expression of GLUT3 and glycolytic metabolism by activating the TGF‐β‐ZEB1 pathway in tumor cells. Conversely, ANGPTL2 suppression in tumor cells decreased GLUT3 expression and blocked glycolytic metabolism. Notably, we observed a positive correlation between ANGPTL2 and GLUT3 expression in primary tumors from patients with lung cancer. Overall, our findings show that tumor cell‐derived ANGPTL2 signaling increases GLUT3 expression through the TGF‐β‐ZEB1 pathway, enhancing glycolytic metabolism (Figure [7](#cas14337-fig-0007){ref-type="fig"}).

![Model of proposed molecular mechanism underlying angiopoietin‐like protein 2 (ANGPTL2)‐mediated metabolic reprogramming. In lung cancer cells, tumor cell‐derived ANGPTL2 activates the transforming growth factor‐β (TGF‐β)‐zinc finger E‐box binding homeobox 1 (ZEB1) pathway through integrin α5β1‐ERK and induces not only the epithelial‐mesenchymal transition (EMT) but also glucose transporter 3 (GLUT3) expression, enhancing glycolytic metabolism](CAS-111-1241-g007){#cas14337-fig-0007}

The tumor microenvironment, which is characterized by hypoxia and/or undernutrition, accelerates production of tumor cell‐derived humoral factors, such as cytokines and growth factors, leading to the EMT in tumor cells.[29](#cas14337-bib-0029){ref-type="ref"}, [30](#cas14337-bib-0030){ref-type="ref"} Epithelial‐mesenchymal transition‐dependent tumor invasion and metastasis is accompanied by increased cancer cell stemness and drug resistance.[31](#cas14337-bib-0031){ref-type="ref"} Furthermore, more recent studies report that the EMT is associated with altered metabolism in cancer cells[32](#cas14337-bib-0032){ref-type="ref"} and that EMT‐induced metabolic reprogramming in favor of glycolytic phenotypes promotes tumor aggressiveness.[33](#cas14337-bib-0033){ref-type="ref"} We previously showed that hypoxia and undernutrition increase ANGPTL2 expression in tumor cells and thereby enhance tumor cell metastatic capacity.[19](#cas14337-bib-0019){ref-type="ref"} The present study now shows that ANGPTL2 induces not only the EMT but also metabolic reprogramming in lung cancer cells through activating the TGF‐β pathway. These findings show that, in the tumor microenvironment, tumor cell‐derived ANGPTL2 serves as an important mediator of both EMT induction and metabolic reprogramming in tumor cells, enhancing tumor aggressiveness.

Mechanistically, we reveal here that activation of ANGPTL2‐dependent glycolytic metabolism is attributable to TGF‐β signaling activated in tumor cells. Accordingly, we previously reported that ANGPTL2 upregulates TGF‐β expression through integrin α5β1‐ERK signaling in renal tubular epithelial cells and macrophages.[28](#cas14337-bib-0028){ref-type="ref"} Moreover, we also reported that ANGPTL2 increases TGF‐β expression through the integrin α5β1‐p38‐MAPK pathway in osteosarcoma cells.[21](#cas14337-bib-0021){ref-type="ref"} Our findings strongly suggest that ANGPTL2 activity upregulates TGF‐β expression through integrin α5β1‐ERK signaling. Hence, we conclude that ANGPTL2‐activated ERK and/or p38 MAPK signaling contributes to activation of the TGF‐β pathway in lung cancer cells, thereby increasing ZEB1 and GLUT3 expression and activating glycolytic activity. Interestingly, others report that nuclear factor‐κB (NF‐κB) contributes to *ZEB1* induction in cancer cells[34](#cas14337-bib-0034){ref-type="ref"} and that NF‐κB increases *GLUT3* expression in cancer cells.[35](#cas14337-bib-0035){ref-type="ref"} Because ANGPTL2‐integrin α5β1 signaling activates the NF‐κB pathway in tumor cells,[21](#cas14337-bib-0021){ref-type="ref"} it is now of interest to investigate whether NF‐κB functions in ANGPTL2‐integrin α5β1 signaling‐mediated upregulation of *GLUT3* expression in lung cancer cells.

To produce ATP as energy and to maintain cellular survival, nontumor epithelial cells rely primarily on mitochondrial oxidative phosphorylation. In contrast, cancer cells produce ATP primarily through glycolysis, regardless of whether cellular conditions are aerobic or not, a metabolic switch known as the Warburg effect.[36](#cas14337-bib-0036){ref-type="ref"}, [37](#cas14337-bib-0037){ref-type="ref"} Enhanced glycolytic metabolism seen in cancer cells is due to induction of glycolysis‐related genes, including GLUT factors.[38](#cas14337-bib-0038){ref-type="ref"} Glucose transporter 1 is reportedly expressed in various cancers, including brain, colon, and lung cancers, and contributes to glucose uptake in those tumor cells.[39](#cas14337-bib-0039){ref-type="ref"}, [40](#cas14337-bib-0040){ref-type="ref"}, [41](#cas14337-bib-0041){ref-type="ref"} Similar to GLUT1, GLUT3 is also expressed in some cancers, including lung cancer.[27](#cas14337-bib-0027){ref-type="ref"}, [41](#cas14337-bib-0041){ref-type="ref"} Both GLUT1 and GLUT3 expression in tumor cells reportedly correlates with poor prognosis of lung cancer patients.[9](#cas14337-bib-0009){ref-type="ref"} Conversely, several studies report that suppressing GLUT expression in tumor cells blocks tumor progression.[42](#cas14337-bib-0042){ref-type="ref"}, [43](#cas14337-bib-0043){ref-type="ref"} The present study indicates that ANGPTL2 expression is correlated with GLUT3 expression in primary tumors from patients with lung cancer. Moreover, our in vitro experiments using lung cancer lines reported here revealed that ANGPTL2 signaling increases GLUT3 expression and enhances glycolytic metabolism, whereas ANGPTL2 suppression decreased GLUT3 expression and antagonized glycolytic metabolism. These findings are consistent with our previous reports that ANGPTL2 expression in tumor cells correlates with metastatic ability and invasiveness of cancer cells and poor prognosis of cancer patients.[19](#cas14337-bib-0019){ref-type="ref"} They also suggest that ANGPTL2‐dependent GLUT3 expression in tumor cells might underlie poor prognosis of lung cancer patients both by activating glycolytic metabolism and increasing cancer malignancy.

In summary, we show that tumor cell‐derived ANGPTL2 enhances glycolytic metabolism in lung cancer cells by increasing *GLUT3* expression through the integrin α5β1‐TGF‐β‐ZEB1 pathway. We also show that ANGPTL2 knockdown inactivates glycolytic metabolism in lung cancer cells. Based on these findings, we propose that tumor cell‐derived ANGPTL2 regulates the preference for glycolytic metabolism in cancer cells. Taken together with our previous reports that ANGPTL2 promotes aggressive metastatic phenotypes by activating tumor cell motility and invasiveness and the EMT, tumor cell‐derived ANGPTL2 could be a therapeutic target useful to antagonize cancer malignancy.
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